Flumazenil subcutaneous- Go Medical Industries

Drug Profile

Flumazenil subcutaneous- Go Medical Industries

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Go Medical Industries
  • Class Antidotes; Benzodiazepinones
  • Mechanism of Action GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Alcoholism

Most Recent Events

  • 15 Feb 2017 Chemical structure information added
  • 24 Feb 2016 Phase-II/III clinical trials in Alcoholism (Alcohol withdrawal syndrome) in Australia (SC) (ACTRN12617000039381)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top